Sinotherapeutics Inc. A Asset Resilience Ratio
Sinotherapeutics Inc. A asset resilience ratio. Sinotherapeutics Inc. A (688247) has an Asset Resilience Ratio of 43.56% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Sinotherapeutics Inc. A defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Sinotherapeutics Inc. A (2024–2025)
Asset resilience ratio of Sinotherapeutics Inc. A from 2024 to 2025. This chart shows how Sinotherapeutics Inc. A's Asset Resilience Ratio has changed over time. Read Sinotherapeutics Inc. A (688247) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Sinotherapeutics Inc. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Sinotherapeutics Inc. A's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥633.46 Million | 43.56% |
| Total Liquid Assets | CN¥633.46 Million | 43.56% |
Asset Resilience Insights
- Very High Liquidity: Sinotherapeutics Inc. A maintains exceptional liquid asset reserves at 43.56% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Sinotherapeutics Inc. A Industry Peers by Asset Resilience Ratio
Compare Sinotherapeutics Inc. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 29.37% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Sinotherapeutics Inc. A Asset Resilience Ratio by Year (2024–2025)
Sinotherapeutics Inc. A asset resilience ratio by year from 2024 to 2025. The table below shows the annual Asset Resilience Ratio data for Sinotherapeutics Inc. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 23.60% | CN¥339.34 Million ≈ $49.66 Million |
CN¥1.44 Billion ≈ $210.44 Million |
-11.34pp |
| 2024-12-31 | 34.94% | CN¥507.74 Million ≈ $74.30 Million |
CN¥1.45 Billion ≈ $212.66 Million |
-- |
About Sinotherapeutics Inc. A
Sinotherapeutics Inc., a specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. The company's products are indicated for infection, oncology and rheumatology, gastroenterology and metabolism, neurology, cardiology, and nephrology. It offers posaconazole delayed-release tablets; olaparib, exemestane, and tofacitinib extende… Read more